知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

818 条记录 (耗时 0.063 秒)

    Therapeutic agents useful for treating pain
    64.
    发明授权
    Therapeutic agents useful for treating pain 有权
    用于治疗疼痛的治疗剂

    公开(公告)号：US09434721B2

    公开(公告)日：2016-09-06

    申请号：US14099738

    申请日：2013-12-06

    申请人： Purdue Pharma L.P.

    发明人： Qun Sun ,  Laykea Tafesse ,  Sam Victory

    IPC分类号： C07D417/12 ,  C07D403/12 ,  C07D401/12 ,  C07D413/12 ,  A61K31/495

    CPC分类号： C07D417/12 ,  A61K31/495 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12

    摘要： A compound of formula: wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound are disclosed.

    Azetidine-substituted quinoxalines as opioid receptor like-1 modulators
    66.
    发明授权
    Azetidine-substituted quinoxalines as opioid receptor like-1 modulators 有权
    氮杂环丁烷取代的喹喔啉作为阿片受体1型调节剂

    公开(公告)号：US09290488B2

    公开(公告)日：2016-03-22

    申请号：US14361876

    申请日：2012-11-30

    申请人： Purdue Pharma L.P. ,  Shionogi & Co., Ltd.

    发明人： Laykea Tafesse ,  Naoki Tsuno ,  Xiaoming Zhou

    IPC分类号： A61K31/498 ,  C07D241/44 ,  C07D413/14 ,  C07D401/14

    CPC分类号： C07D413/14 ,  C07D401/14

    摘要： The disclosure relates to Azetidine-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein the R1, R2, R3, Q, Y1, Z, A, B, a, and b are as defined herein, compositions comprising an effective amount of an Azetidine-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Azetidine-Substituted Quinoxaline-Type Piperidine Compound.

    摘要翻译： 本公开涉及式（I）的氮杂环丁烷取代的喹喔啉型哌啶化合物及其药学上可接受的衍生物，其中R 1，R 2，R 3，Q，Y 1，Z，A，B，a和b如本文所定义， 包含有效量的氮杂环丁烷取代的喹喔啉哌啶化合物的组合物，以及治疗或预防诸如疼痛的病症的方法，包括向有需要的动物施用有效量的氮杂环丁烷取代的喹喔啉型哌啶化合物 。

    TRANSDERMAL DELIVERY SYSTEM
    69.
    发明申请
    TRANSDERMAL DELIVERY SYSTEM 审中-公开

    公开(公告)号：US20160008294A1

    公开(公告)日：2016-01-14

    申请号：US14772474

    申请日：2014-06-04

    申请人： PURDUE PHARMA L.P.

    发明人： Thomas HILLE ,  Gabriel Wauer ,  Frank Seibertz ,  Shu-Lun Weinheimer

    IPC分类号： A61K9/70 ,  A61K9/00 ,  A61F13/02 ,  A61K31/485

    CPC分类号： A61K31/4748 ,  A61F13/0256 ,  A61K9/0014 ,  A61K9/7053 ,  A61K9/7069 ,  A61K31/485 ,  A61K47/12 ,  A61K47/32

    摘要： The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of said buprenorphine-containing pressure-sensitive adhesive layer, and d) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture including said viscosity-increasing substance, and wherein the carboxylic acid-, buprenorphine- and viscosity-increasing substance-containing mixture forms dispersed deposits in the said pressure-sensitive adhesive, and wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.